tagraxofusp + decitabine

Tagraxofusp + decitabine is an investigational combination therapy being evaluated for the treatment of myeloid malignancies, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Tagraxofusp (Elzonris) is a first-in-class CD123-targeted therapy composed of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT388) payload. It functions by binding to the IL-3 receptor alpha chain (CD123) on the surface of malignant cells, internalizing, and subsequently inhibiting protein synthesis via ADP-ribosylation of elongation factor 2, leading to apoptosis. Decitabine is a hypomethylating agent that acts as a nucleoside metabolic inhibitor; it incorporates into DNA and inhibits DNA methyltransferases, resulting in DNA hypomethylation and the restoration of normal function to genes critical for cellular differentiation and proliferation. This combination is currently being investigated in a Phase I/II clinical trial (NCT05038592) sponsored by the M.D. Anderson Cancer Center to determine the safety and efficacy of the regimen in patients with high-risk myeloid disorders.

Brand names

Elzonris

Other names

tagraxofusp-erzs + decitabineSL-401 + decitabine